Radiopharm Theranostics (ASX:RAD) Receives FDA Designations for DUNP19
Radiopharm Theranostics CEO and Managing Director Riccardo Canevari discusses the FDA’s award of orphan status and rare paediatric disease designation for the company’s DUNP19 technology.
Read More